This site is intended for healthcare professionals
  • Home
  • /
  • News & Insights
  • /
  • News trends
  • /
  • Biosimilars
  • /
  • Biosimilars: an option to alleviate the heavy burd...
News

Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases

Read time: 10 mins
Last updated:16th Jul 2021
Published:16th Jul 2021
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Developed by EPG Health for Medthority in collaboration with Biogen who provided some of the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.